相关实验视频
Updated: Jul 23, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.6K
PHB2通过与NDUFV2的相互作用和线粒体复合体I功能的恢复来改善多克索鲁比诱导的心肌病
Mingjie Yang1, Miyesaier Abudureyimu2, Xiang Wang1
1Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, 200032, China; National Clinical Research Center for Interventional Medicine, Shanghai, 200032, China.
Redox biology
|July 14, 2023
概括
禁忌素2 (PHB2) 缺乏症通过损害线粒体功能和NDUFV2稳定性,加剧了多克索鲁比 (DOX) 的心脏毒性. 过度表达PHB2可能为DOX诱导的心脏损伤提供治疗策略.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- doxorubicin (DOX) 是一种广泛使用的化疗剂,具有显著的心脏毒性.
- 线粒体损伤是DOX诱导心肌病的关键因素.
- 禁止素2 (PHB2) 在DOX心脏毒性的作用尚不清楚.
研究的目的:
- 调查PHB2在DOX心脏毒性病理发生中的作用.
- 在DOX诱导的心脏损伤的背景下,识别PHB2的下游媒介.
主要方法:
- 产生了特定于心脏的PHB2条件淘汰赛小鼠.
- 接受多克索鲁比辛挑战的小鼠,并评估心脏功能和线粒体配置文件.
- 利用蛋白质基因分析,生物信息分析,共免疫沉和拉下测试来识别PHB2相互作用伙伴.
主要成果:
- 在DOX-挑战的心脏中,PHB2表达被降低了.
- 缺乏PHB2使DOX心脏毒性恶化,导致心脏缩,纤维化和心脏功能减弱.
- 由于PHB2缺乏,线粒体的生物能学和氧化酸化受损.
- PHB2与线粒体复合体I的子单元NDUFV2相互作用,稳定其表达.
- PHB2缺乏导致DOX挑战心脏的NDUFV2水平降低.
- 心脏过度表达PHB2改善了DOX诱导的线粒体缺陷.
结论:
- 通过与NDUFV2的相互作用,PHB2在DOX挑战的心脏中维持线粒体动力学和能量代谢方面发挥着关键作用.
- 对NDUFV2的PHB2稳定对于减轻DOX心脏毒性至关重要.
- 过度表达PHB2为DOX心肌病症提供了潜在的治疗途径.
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:29Cardiomyopathy V: Interprofessional Care
17
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
17
01:46Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14